TheraRadar

Briefs tagged "diagnostics"

1 brief

APOLLO-B ATTR amyloidosis ATTR-CM AbbVie Alnylam Amgen Amvuttra Arvinas Attruby BMS Biogen CNS CRISPR Therapeutics Eisai Eli Lilly FDA HELIOS-B IBD IGF-1R J&J Merck Novartis Onpattro Pfizer Regeneron Roche Sandoz Sanofi TL1A TTR Takeda Vertex acoramidis autoimmune biomarkers biosimilars bispecific cardiology cardiovascular clinical trials competitive landscape diagnostics drug development gene therapy genetics hATTR-PN immunotherapy metabolic oncology ophthalmology patent cliff patisiran precision medicine protein degradation rare disease regulatory tafamidis trial design vutrisiran
11 min read

The Disease That Wasn't Rare After All

The scan that finds it is quick, safe, and has been around for years. Almost no cardiologist used it until a drug gave them a reason to look.

A non-invasive scan could spot ATTR cardiac amyloidosis, a common, deadly, long-overlooked cause of heart failure in the elderly, years before doctors used it. Diagnoses only surged after tafamidis (Vyndaqel) was approved for the heart in 2019. The treatment didn't create the disease; it created the diagnosis. The backstory, the economics, and why it matters.

Read the full brief
ATTR amyloidosiscardiologytafamidisPfizerrare diseasedrug development

Get the next Brief in your inbox — free

Every drug has multiple stories. Most never get told. One brief every week. No spam.

or just get the emails

Archive at /briefs/. Unsubscribe anytime.